

AN INDEPENDENT CERTIFIED SESSION AT ACC.19

Controversies and Consensus in the Prevention and Management of Cardiovascular Disease in 2019

COMPLIMENTARY DINNER SYMPOSIUM

March 15, 2019

7:00-9:15 PM

The Westin New Orleans Canal Place

Register Today: www.ccfcmec.org/CVprevention

Description

By the year 2020, CVD is estimated to become the leading cause of death and disability worldwide. Despite this high prevalence, evidence increasingly suggests that the atherosclerotic process can be greatly slowed and its mortality markedly reduced.

This program will focus on cardiovascular disease risk assessment and current and evolving management of major risk factors, including hypertension, hyperlipidemia and diabetes. With the availability of newer pharmaceuticals and technology, clinicians are challenged to stay up to date with this information and will benefit from expert interpretation on the latest data and implications for clinical care.

Learning Objectives

- Critically assess the often conflicting recommendations for lipid and hypertension management, the underlying evidence, and the implications for clinical practice
- Recognize the implications of diabetes on cardiovascular disease and treatment outcomes and tailor management accordingly
- Incorporate the evidence on contemporary treatment options into clinical decision-making for patients with CAD
- Analyze the impact of non-invasive imaging in predicting the risk for CVD
- Assess the potential impact of digital health technology on population health



Cleveland Clinic has been ranked the nation's No. 1 heart care program for 24 consecutive years by *U.S. News & World Report*.

AN INDEPENDENT CERTIFIED SESSION AT ACC.19

Controversies and Consensus in the Prevention and Management of Cardiovascular Disease in 2019

COMPLIMENTARY DINNER SYMPOSIUM

March 15, 2019

7:00-9:15 PM | The Westin New Orleans Canal Place

Agenda

Chairs: *Steven Nissen, MD and Leslie Cho, MD*

7:00 PM	Registration and Dinner Buffet	8:30 PM	How I manage Stable Multi Vessel Disease: PCI vs. CABG vs. Medical Therapy <i>Faisal Bakaeen, MD</i>
7:30 PM	Use of Noninvasive Atherosclerosis Imaging to Improve CV Risk Assessment <i>Wael Jaber, MD</i>	8:45 PM	Mobile Health Technology: The Potential to Transform the way we Prevent and Manage Heart Disease? <i>Kaldoun Tarakji, MD</i>
7:45 PM	Targeting Dyslipidemia: Current and Future Therapies <i>Steven Nissen, MD</i>	9:00 PM	Panel Discussion and Audience Q & A
8:00 PM	From Clinical Trials to Clinical Practice: Applying Cardiovascular Outcome Trial Data to Real World T2DM Management <i>Venu Menon, MD</i>	9:15 PM	Adjourn
8:15 PM	Practical Considerations in Hypertension Guideline Implementation <i>Leslie Cho, MD</i>		

Register Today www.ccfcm.org/CVprevention

This activity has been approved for *AMA PRA Category 1 Credit™*



Co-Activity Directors

Steven Nissen, MD
Cleveland Clinic
Cleveland, OH

Katherine Hoercher, RN
Cleveland Clinic
Cleveland, OH

Faculty

Faisal Bakaeen, MD
Cleveland Clinic
Cleveland, OH

Leslie Cho, MD
Cleveland Clinic
Cleveland, OH

Wael Jaber, MD
Cleveland Clinic
Cleveland, OH

Venu Menon, MD
Cleveland Clinic
Cleveland, OH

Steven Nissen, MD
Cleveland Clinic
Cleveland, OH

Kaldoun Tarakji, MD
Cleveland Clinic
Cleveland, OH

This educational activity is not part of ACC.19; however, the content was reviewed and approved by the ACC.19 Program Committee.